MAP3K9 is a serine/threonine kinase that functions as an upstream activator of the MKK/JNK signal transduction cascade, phosphorylating MAP2K4/MKK4 and MAP2K7/MKK7 to activate JNK signaling and regulate stress responses through transcription factors like AP-1 and GATA4. The protein also participates in mitochondrial death signaling pathways leading to apoptosis. MAP3K9 expression is tightly regulated by microRNA-mediated mechanisms. miR-148b, miR-23, miR-125b-5p, and miR-361-5p directly target MAP3K9 mRNA to suppress its protein levels 1 2 3 4. Additionally, circUGGT2 acts as a competing endogenous RNA, sponging miR-186-3p to upregulate MAP3K9 5. Post-translational regulation occurs via CBLB-mediated K48-K63-linked polyubiquitination at Lys193, targeting MAP3K9 for proteasomal degradation and suppressing MAPK-P38 pathway activation 6. Dysregulated MAP3K9 expression contributes to multiple pathologies. Elevated MAP3K9 promotes gastric cancer chemoresistance and progression through JNK signaling 5 2, enhances renal cancer proliferation and impairs apoptosis 1, increases glioblastoma invasion 6, and exacerbates shoulder arthritis progression by activating MMP expression 4. Conversely, MAP3K9 suppression by microRNA elevation correlates with improved survival and reduced malignancy in laryngeal squamous cell carcinoma 3. These findings establish MAP3K9 as a critical oncogenic hub amenable to therapeutic targeting.